2Boon J,Hoy AJ,Stark R, et al. Ceramides contained in LDL are elevatedin type 2 diabetes and promote inflammation and skeletal muscle insulinresistancep]. Diabetes,2013,62(2) :401-410.
4Vinodh R,Hannun YA. Sphingolipid metabolism and signaling as a targetfor cancer treatment[J]. Cell Death Dis,2013 ,28(4) :205-229.
5Venable ME. Elevation of Ceramide in Senescence : Role of SphingolipidMetabolism[J]. Tumor Dormancy ,2014,32(2) :81-88.
6Goni FM,Sot J,Alonso A. Biophysical properties of sphingosine,ceramidesand other simple sphingolipids [J]. Biochem Soc Trans,2014,42 (5):1401-1408.
7Airola MV, Hannun YA. Sphingolipid metabolism and neutral sphingo-myelinasesfj]. Handb Exp Pharmacol,2013(215) :57-76.
8Chang ZQ,Lee SY,Kim HJ, et al. Endotoxin activates de novo sphingo-lipid biosynthesis via nuclear factor kappa B-mediated upregulation ofSptlc2[J]. Prostaglandins Other Lipid Mediat,2011,94(1/2) :44-52.
9Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-a-inducedliver injury : role of IKK,JNK,and ROS pathways [J]. Am J Physiol Gas-trointest Liver Physiol,2006,290(4) : G583-589.
10Holland WL,Summers SA. Sphingolipids,insulin resistance,and metabolicdisease : new insights from in vivo manipulation of sphingolipid metabo-lism[J]. EndocrRev,2008,29(4):381-402.
二级参考文献16
1Kim D, Kim WR, Kim HI, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States[J]. Hepatology, 2013, 57: 1357- 1365.
2Park SK, Seo MH, Shin HC, et al. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men; 5-year prospective cohort study[J]. Hepatology, 2013, 57: 1378-1383.
3Vazquez-Chanteda M, Gonzalez-Lahera A, Martinez-Arranz I, et al. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57: 505-514.
4Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan[J]. Hum Genet, 2013, 132: 783-792.
5Adams LA, White SW, Marsh JA, et al. Association between liver- specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57: 590-600.
6Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2013, 58: 120-127.
7Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients; a connection between endogenous alcohol and NASH[J]. Hepatology, 2013, 57: 601-609.
8Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secmtome[J]. Nature, 2013, 499: 97-101.
9Verdam F J, Dallinga JW, Driessen A, et al. Non-alcoholic steatohepatitis; a non-invasive diagnosis by analysis of exhaled breath[J]. J Hepatol, 2013, 58: 543-548.
10Li H, Dong K, Fang Q, et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease; a 3-year prospective study in China[J]. J Hepatol, 2013, 58: 557-563.
